GUIDEPOINT INSIGHTS ESMO VIRTUAL GROUP MEETINGS
Guidepoint Insights will be hosting a series of 12, 45-minute virtual group meetings on Sunday, September 20th, and Monday, September 21, with KOLs who will dive deeper into ESMO clinical data updates and discuss the impact on treatment paradigms.
Sunday, September 20, 10:00 AM
Pamela Munster | Breast Cancer | Professor of Medicine at The University of California, San Francisco
- Analysis of Trodelvy (sacitizumab govitecan) across mTNBC in phase 3 ASCENT study
- Discussion of potential additional indications and lines of therapy Trodelvy can be used for
- Implications of GILD acquisition of IMMU
- Review of SGEN’s Tukysa (tucatinib), PFS in HER2+ mBC and stable or active brain metastases
- ALKS 4230 mono and in combination with pembro (ARTISTRY-1)
- Overview of emerging Oral SERDs
- Additional developing therapies presented at ESMO and changing competitive landscape across mBC
Sunday, September 20, 11:00 AM
Neeraj Agarwal | GU Cancer | Professor at Huntsman Cancer Institute University of Utah Health
- Overview of RCC competitive landscape
- Review of Myovan’ts relugolix in advanced prostate cancer with PDUFA on 12/20/2020
- Review of phase 2 KEYNOTE-158 study
- Use of Trodelvy (sacitizumab govitecan) in bladder cancer in TROPHY-U-01 Cohort
Sunday, September 20, 12:00 PM
Adi Diab | Melanoma and Immuno-oncology | Assistant Professor at The University of Texas MD Anderson Cancer Center
- MRK/BMY: Adjuvant pembro (Keynote 054) and nivo +ipi (CheckMate 238) and how this might shift treatment paradigm and usage of PD-1s going forward
- MRK/ESALY/IDRA: Lenvatinib + pembro (LEAP-004) in PD-1/PD-L1 relapsed patients and competitive landscape in post-checkpoint inhibitor setting including ILLUMINATE-204 (tilsotolimod) and LEAP-005 data in solid tumors
- NVS/BMY/RHHBY: The future of 1L IO in BRAFm melanoma – P3 Data for Spart-dabtram in BRAF V600 patients at ESMO vs. IMspire150 vs. CM-067
- INCY/MGNX: POD1UM-201: P2 retifanlimab (INCMGA00012) in MCC
- KPTI: Selinexor + pembro in melanomna
Sunday, September 20, 1:00 PM
Jason Luke | Developmental Therapeutics | Director of Immunotherapeutics Center at UPMC Hillman Cancer Center
- PIRS: A ph1 dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies
- MGNX: P1 data from MGD019 – bispecific PD-1 x CTLA-4 DART in advanced solid tumors
- AMGN: BiTEs in Solid tumors – PSMA-targeting/AMG 160 and CLDN18.2/AMG 910
- ALKS: ALKS 4230 (ARTISTRY01) mono and combo w/ pembro in refractory solid tumors
- KPTI: Selinexor + pembro in melanomna
Sunday, September 20, 2:00 PM
Michael Morse | GI Cancer | Professor of Medicine at Duke University Health System, Inc.
- Discussion of phase 3 KEYNOTE-177 study
- Use of pembro vs. chemo in 1L in MSI-H or dMMR mCRC
- Analysis of interim data of NUC-7738 NuTide 701 study
- Review of NUC-33¶3 with or without leucovorin in mCRC and NUC-1031 plus cisplatin vs gemcitabine plus cisplatin for 1L advanced biliary tract cancer
- CheckMate-649 study of nivolumab in 1L
- Tislelizumab w/ VENTANA-PD-L1
- Overview of GI competitive landscape
Monday, September 21, 8:00 AM
Aurelien Marabelle | Immuno-oncology | Clinical Director, Cancer Immunotherapy Program at Institut de cancérologie Gustave Roussy
- GSK/MKGAF: TGF-beta Trap data across indications including 3-year follow up in 2L NSCLC
- MRK/ESALY/IDRA: Lenvatinib + pembro (LEAP-004) in PD-1/PD-L1 relapsed patients and competitive landscape in post-checkpoint inhibitor setting including ILLUMINATE-204 (tilsotolimod) and LEAP-005 data in solid tumors
- SBPH: P1/1b of a STING agonist SB 11285 mono or combo with nivo in advanced solid tumors
- MRK/BMY: Adjuvant pembro (Keynote 054) and nivo +ipi (CheckMate 238) and how this might shift treatment paradigm and usage of PD-1s going forward
- Servier: P1 Study of Sym021 (PD-1) mono or in combo with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
Monday, September 21, 10:00 AM
Jared Weiss | Lung Cancer and Head and Neck Cancer | Associate Professor at University of North Carolina at Chapel Hill
- KRAS G12C inhibitor data, EGFR landscape, and IO neoadjuvant evidence in NSCLC
- Coverage of ES-SCLC PACIFIC and CASPIAN studies
Monday, September 21, 11:00 AM
Scott Tagawa | GU Cancer | Professor at Weill Cornell Medical College, New York
- Analysis of IMMU-132 Phase 2 trial of Trodelvy (sacitizumab govitecan) in metastatic urothelial cancer
- Review of Myovan’ts relugolix in advanced prostate cancer with PDUFA on 12/20/2020
- Phase 1b/2 data of VERU-111 (bisindole) in prostate cancer
Monday, September 21, 12:00 PM
Frank Giles | Developmental Therapeutics | Former Director at Northwestern University
- BMY: CC-90011 in patients with advanced solid tumors and r/r non-hodgkin lymphoma: updated results of a ph1 study
- PIRS: A ph1 dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies
- RHHBY: FAP-Targeted 4-1BB agonist, mono + combo w/ atezo in solid tumors
- MGNX: P1 data from MGD019 – bispecific PD-1 x CTLA-4 DART in advanced solid tumors
- MRK/AGEN: Initial Results of a ph1 study of MK-4830, a first in class anti-immunoglobulin-like transcript 4 (ILT4) myeloid specific antibody in patients with advanced solid tumors
Monday, September 21 1:00 PM
Premal Thaker | GYN Cancer | Professor at Washington University, St. Louis
- Analysis of SGEN’s Phase 2 innovaTV 204 trial for tisotumab vedotin in cervical cancer
- Discussion of single-agent Anti-PD-1 Balstilimab or in combination with Zalifrelimab
- Review of MRSN’s NaPi2b targeted ADC XMT-1536’s interim data readout
- ALKS 4230 mono and in combination with pembro (ARTISTRY-1)
- Luatinib+Nivo in gynecological tumors
- Overview of cervical and ovarian cancer competitive landscape
Monday, September 21, 2:00 PM
Carlos Caldas | Breast Cancer | Professor of Cancer Medicine at University of Cambridge
- Analysis of Trodelvy (sacitizumab govitecan) across mTNBC in phase 3 ASCENT study
- Discussion of potential additional indications and lines of therapy Trodelvy can be used for
- Implications of GILD acquisition of IMMU
- Overview of emerging Oral SERDs
- Review of SGEN’s Tukysa (tucatinib), PFS in HER2+ mBC and stable or active brain metastases
- ALKS 4230 mono and in combination with pembro (ARTISTRY-1)
- Additional developing therapies presented at ESMO and changing competitive landscape across mBC
Monday, September 21, 3:00 PM
Vamsidhar Velcheti | Lung Cancer | Director for Thoracic Oncology Program at NYU Langone Medical Center LLC
- KRAS G12C inhibitor data, EGFR landscape, and IO neoadjuvant evidence in NSCLC
- Coverage of ES-SCLC PACIFIC and CASPIAN studies
This event has passed.
To request access to future group meetings, complete the form below.
